601567:SSENingbo Sanxing Medical Electric Co., Ltd. Class A Analysis

The stock is trading at CNY 17, just below the computed resistance of 17.15 and well above the support of 13.17, with the 20‑day SMA (14.54) and 50‑day SMA (15.18) already under the price, suggesting a short‑term price cushion. However, the overall trend is flagged as bearish and the 200‑day SMA (22.30) remains far higher, underscoring a long‑term downtrend. Momentum indicators are mixed: RSI sits at 68.4, edging into overbought territory, while the MACD histogram is positive and the signal line is bullish, hinting at a possible near‑term bounce. Trading volume is increasing, but volatility is extreme at over 50% for the past 30 days, and beta is low (0.55), indicating the stock moves less than the market but can swing sharply. Fundamentally, revenue fell 10.8% YoY, margins are thin (gross 26%, operating 6%), and ROE is modest at 7.5%, reflecting limited growth momentum. The balance sheet shows CNY 5.5 bn in cash versus CNY 6.1 bn of debt, yielding a debt‑to‑equity of 51%, which adds financial strain. While the dividend yield appears attractive at 9.4%, the payout ratio exceeds 200%, raising serious sustainability concerns. Valuation metrics are mixed: the trailing PE of 25.4 is below the industry average of 30.3, yet the DCF‑derived fair value of CNY 2.46 is dramatically lower than the market price, implying potential overvaluation. Overall, the stock faces high short‑term risk with limited upside, a questionable dividend policy, and a need for earnings recovery to justify its price.